The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients

Pharmacogenomics

Volumn 12, Issue 9, 2011, Pages 1281-1291

  De Jonge, Hylke ^a   Metalidis, Christoph ^a   Naesens, Maarten ^a   Lambrechts, Diether ^b   Kuypers, Dirk R J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

28 C>T; calcineurin inhibitor n CYP3A4; CYP3A5; dose requirements; P450 oxidoreductase; pharmacokinetics; POR; renal transplantation; SNPs; tacrolimus

Indexed keywords

CYTOCHROME P450 3A; CYTOCHROME P450 REDUCTASE; CYTOSINE; ISOENZYME; METHYLPREDNISOLONE; MIDAZOLAM; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMINE; CYP3A5 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE;

ACUTE GRAFT REJECTION; ADULT; ALLELE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYP3A5 GENE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE; GRAFT RECIPIENT; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; FOLLOW UP; GENETICS; KIDNEY TRANSPLANTATION; METABOLISM; MIDDLE AGED;

ADULT; AGED; ALLELES; CYTOCHROME P-450 CYP3A; FEMALE; FOLLOW-UP STUDIES; GENETIC ASSOCIATION STUDIES; GENOTYPE; HETEROZYGOTE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NADPH-FERRIHEMOPROTEIN REDUCTASE; POLYMORPHISM, SINGLE NUCLEOTIDE; TACROLIMUS;

EID: 80052922074     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.77     Document Type: Article

References (33)

1. Venkataramanan R, Swaminathan A, Prasad T et al. Clinical pharmacokinetics of tacrolimus. Clin. Pharmacokinet. 29(6), 404-430 (1995). (Pubitemid 26004179)
2. Kuypers DR, Claes K, Evenepoel P et al. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Clin. Pharmacokinet. 43(11), 741-762 (2004). (Pubitemid 39159005)
3. Lampen A, Christians U, Guengerich FP et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab. Dispos. 23(12), 1315-1324 (1995). (Pubitemid 26007838)
4. Kamdem LK, Streit F, Zanger UM et al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin. Chemistry 51(8), 1374-1381 (2005). (Pubitemid 41060869)
5. Möller A, Iwasaki K, Kawamura A et al. The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab. Dispos. 27(6), 633-636 (1999). (Pubitemid 29252435)
6. de Jonge H, Kuypers DR. Pharmacogenetics in solid organ transplantation: current status and future directions. Transplant. Rev. 22(1), 6-20 (2008). (Pubitemid 350131580)
7. Jacobson PA, Oetting WS, Brearley AM et al Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. Transplantation 91(3), 300-308 (2011).
8. Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin. Pharmacol. Ther. 82(6), 711-725 (2007). (Pubitemid 350114816)
9. Macphee IA, Fredericks S, Tai T et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 74(11), 1486-1489 (2002). (Pubitemid 36014218)
10. Hesselink DA, van Schaik RH, van der Heiden IP et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 74(3), 245-254 (2003). (Pubitemid 37083100)
11. Thervet E, Loriot MA, Barbier S et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin. Pharmacol. Ther. 87(6), 721-729 (2010).
12. Huang N, Agrawal V, Giacomini KM, Miller WL. Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc. Natl Acad. Sci. USA 105(5), 1733-1738 (2008). (Pubitemid 351346583)
13. Agrawal V, Huang N, Miller WL. Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19. Pharmacogenet. Genomics 18(7), 569-576 (2008).
14. Masters BS. The journey from NADPH-cytochrome P450 oxidoreductase to nitric oxide synthases. Biochem. Biophys. Res. Commun. 338(1), 507-519 (2005). (Pubitemid 41540597)
15. Hubbard PA, Shen AL, Paschke R, Kasper CB, Kim JJ. NADPH-cytochrome P450 oxidoreductase. Structural basis for hydride and electron transfer. J. Biol. Chem. 276(31), 29163-29170 (2001).
16. Scott RR, Gomes LG, Huang N, van Vliet G, Miller WL. Apparent manifesting heterozygosity in P450 oxidoreductase defciency and its effect on coexisting 21-hydroxylase defciency. J. Clin. Endocrinol. Metab. 92(6), 2318-2322 (2007). (Pubitemid 46997140)
17. Wang M, Roberts DL, Paschke R, Shea TM, Masters BS, Kim JJ. Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN-and FAD-containing enzymes. Proc. Natl Acad. Sci. USA 94(16), 8411-8416 (1997). (Pubitemid 27335052)
18. Oneda B, Crettol S, Jaquenoud Sirot E, Bochud M, Ansermot N, Eap CB. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmaco genet. Genomics 19(11), 877-883 (2009).
19. Miller WL, Agrawal V, Sandee D et al. Consequences of POR mutations and polymorphisms. Mol. Cell. Endocrinol. 336(1-2), 174-179 (2011).
20. Kuypers DR, Naesens M, de Jonge H, Lerut E, Verbeke K, Vanrenterghem Y. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Ther. Drug Monit. 32(4), 394-404 (2010).
21. Poggio ED, Wang X, Weinstein DM et al. Assessing glomerular fltration rate by estimation equations in kidney transplant recipients. Am. J. Transplant. 6(1), 100-108 (2006). (Pubitemid 43382207)
22. Solez K, Colvin RB, Racusen LC et al. Banff 07 classifcation of renal allograft pathology: updates and future directions. Am. J. Transplant. 8(4), 753-760 (2008). (Pubitemid 351347767)
23. American Diabetes Association. Report of the expert committee on the diagnosis and classifcation of diabetes mellitus. Diabetes Care 26(Suppl. 1), S5-S20 (2003).
24. Davidson J, Wilkinson A, Dantal J et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Transplantation 75(Suppl. 10), SS3-SS24 (2003).
25. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16(3), 1215 (1998).
26. Jurinke C, Oeth P, van den Boom D. MALDI-TOF mass spectrometry: a versatile tool for high-performance DNA ana lysis. Mol. Biotechnol. 26 (2), 147-164 (2004).
27. Tsuchiya N, Satoh S, Tada H et al. Infuence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 78(8), 1182-1187 (2004). (Pubitemid 39426437)
28. Cascorbi I, Gerloff T, Johne A et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. 69(3), 169-174 (2001). (Pubitemid 32225417)
29. Cavalli SA, Hirata MH, Hirata RD. Detection of Mboll polymorphism at the 5́promoter region of CYP3A4. Clin. Chem. 47 (2), 348-351 (2001). (Pubitemid 32142940)
30. Agrawal V, Choi JH, Giacomini KM, Miller WL. Substrate-specifc modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase. Pharmacogenet. Genomics 20(10), 611-618 (2010).
31. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin. Pharmacokinet. 37(6), 485-505 (1999). (Pubitemid 30032252)
32. Kharasch ED, Walker A, Isoherranen N et al. Infuence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol. Ther. 82(4), 410-426 (2007). (Pubitemid 47414348)
33. Williams JA, Cook J, Hurst SI. A signifcant drug-metabolizing role for CYP3A5? Drug Metab. Dispos. 31(12), 1526-1530 (2003).